Combined cutaneous tumors with a melanoma component: A clinical, histologic, and molecular study - 17/08/15
Abstract |
Background |
The histogenesis and clinical behavior of combined cutaneous tumors (CCTs) in which the mesenchymal component consists of melanoma remain unclear.
Objective |
We sought to characterize the clinical, histologic, and molecular findings in CCTs with an epithelial and a melanoma component.
Methods |
We retrospectively reviewed the records from 2 institutions for CCTs. Fluorescence in situ hybridization was performed to assess chromosomal copy number alterations in both components.
Results |
Sixteen CCTs were included. The most common subtype was the squamomelanocytic tumor (11), followed by the basomelanocytic tumor (3) and the trichoblastomelanoma (2). CCTs were more common in men (87%), on the head and neck (57%), and had extensive solar elastosis (81%). The median follow-up was 25 months (range, 8-167 months). One case had an adverse outcome. Fluorescence in situ hybridization revealed chromosomal alterations in approximately 55% of the cases. Five cases showed chromosomal gains only in the melanocytic component. One case showed 11q13 gains in both the epithelial and melanocytic components.
Limitations |
Our study is retrospective and the sample is small.
Conclusions |
The low incidence of adverse outcomes suggests that CCT may be more indolent than noncombined tumors. 11q13 amplification in both components supports the theory of dual differentiation from a common progenitor cell.
Le texte complet de cet article est disponible en PDF.Key words : basomelanocytic tumor, biphenotypia, combined tumor, fluorescence in situ hybridization, melanoma, squamomelanocytic tumor, trichoblastomelanoma
Abbreviations used : BCC, BMT, CCT, FISH, MART1, MITF, PEH, SCC, SMT, TP53
Plan
| Supported by the IDP Foundation. |
|
| Dr Gerami has served as a consultant to and has received honoraria from Castle Biosciences Inc, Myriad Genetics, and DermTech Inc. Dr Guitart has served as a consultant to and received honoraria from DermTech Inc. The other authors have no conflicts of interest to declare. |
Vol 73 - N° 3
P. 451-460 - septembre 2015 Retour au numéro
Article précédent
- Sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients (SOTRs)
- Maryam M. Asgari, Sarah T. Arron, E. Margaret Warton, Charles P. Quesenberry, Dana Weisshaar
- Immunosuppression is an independent prognostic factor associated with aggressive tumor behavior in cutaneous melanoma
- Tracy Donahue, Christina Y. Lee, Asmi Sanghvi, Roxana Obregon, Michael Sidiropoulos, Chelsea Cooper, Emily A. Merkel, Oriol Yélamos, Laura Ferris, Pedram Gerami
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?